MINT-FENOFIBRATE E TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
23-06-2017
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
FENOFIBRATE
可用日期:
MINT PHARMACEUTICALS INC
ATC代码:
C10AB05
INN（国际名称）:
FENOFIBRATE
剂量:
145MG
药物剂型:
TABLET
组成:
FENOFIBRATE 145MG
给药途径:
ORAL
每包单位数:
90
处方类型:
Prescription
治疗领域:
FRIBIC ACID DERIVATIVES
產品總結:
Active ingredient group (AIG) number: 0118895006; AHFS:
授权状态:
CANCELLED POST MARKET
授权日期:
2020-04-28
产品特点
PRODUCT MONOGRAPH
Pr
MINT-FENOFIBRATE E
fenofibrate
film-coated tablets (145 mg)
USP
LIPID METABOLISM REGU
LATOR
Mint Pharmaceuticals Inc.
Date of Preparation:
1093 Meyerside Dr., Unit #1
JUNE 15, 2017
Mississauga, Ontario
L5T 1J6
Submission Control No: 186636
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT
INFORMATION.........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
..................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
14
DOSAGE AND ADMINISTRATION
..............................................................................
18
OVERDOSAGE
.................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 19
STORAGE AND STABILITY
..........................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 21
PART II: SCIENTIFIC INFORMATION
........................................................................
23
PHARMACEUTICAL INFORMATION
..........................................................................
23
CLINICAL TRIALS
..........................................................................................................
24
DETAILED PHARMACOLOGY
.....................................................................................
29
TO
阅读完整的文件
